文献速递心脑血管急症

细胞色素P450 2C19基因型与氯吡格雷在缺血性卒中患者中的应用:一项非随机临床试验

Cytochrome P450 2C19 Genotypes and Clopidogrel in Patients With Ischemic Stroke: A Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2025-04-01
一句话结论在接受氯吡格雷治疗的急性缺血性卒中患者中,CYP2C19功能缺失等位基因携带者6个月内发生心血管事件的风险高于非携带者(2.7% vs 1.6%,log-rank P=0.048)。

该研究为前瞻性非随机临床试验,于2019年9月1日至2023年1月27日在韩国37家临床中心开展,纳入急性缺血性卒中后72小时内接受氯吡格雷治疗的患者2925例,按CYP2C19基因型分为功能缺失(LOF)等位基因携带者与非携带者,比较6个月内的心血管事件风险。主要终点在携带者中发生率高于非携带者(2.7% vs 1.6%,log-rank P=0.048);大出血(0.6% vs 0.8%,P=0.56)和全因死亡(0.3% vs 0.1%,P=0.27)无显著差异。作者结论认为CYP2C19 LOF等位基因携带者发生心血管事件的可能性更高。

要点

  • 在2910例接受氯吡格雷治疗的急性缺血性卒中患者中,CYP2C19 LOF等位基因携带者6个月内主要心血管事件发生率为2.7%,非携带者为1.6%(log-rank P=0.048)。
  • 携带者与非携带者在大出血发生率(0.6% vs 0.8%,P=0.56)和全因死亡率(0.3% vs 0.1%,P=0.27)方面无显著差异。
  • 61.3%的患者被归类为弱代谢型或中间代谢型,38.7%为强代谢型。
  • 该研究为前瞻性非随机临床试验,纳入急性缺血性卒中后72小时内接受氯吡格雷治疗的患者。

适用人群与场景

  • 在急性缺血性卒中后72小时内接受氯吡格雷治疗的患者(研究纳入标准)。
  • 研究于2019年9月1日至2023年1月27日在韩国37家临床中心开展。
  • 共纳入2925例患者,平均(SD)年龄65.3(12.4)岁,1928例(66.3%)为男性。

诊断标准与关键阈值

  • 按CYP2C19基因型分为CYP2C19功能缺失(LOF)等位基因携带者与非携带者。
  • 61.3%的患者被归类为弱代谢型或中间代谢型,38.7%为强代谢型。

处置流程与药物剂量

  • 研究期间维持氯吡格雷治疗。

研究设计与关键结果

  • 研究设计:前瞻性、非随机临床试验(PLATELET试验),在韩国37家临床中心开展,纳入急性缺血性卒中后72小时内接受氯吡格雷治疗的患者,按CYP2C19 LOF等位基因携带状态分组,进行意向性治疗分析。
  • 主要终点:CYP2C19 LOF等位基因携带者6个月内主要心血管事件(包括缺血性或出血性卒中、心肌梗死或心血管死亡)发生率为2.7%(49/1785),非携带者为1.6%(18/1125),log-rank P=0.048。
  • 安全性终点:大出血发生率在携带者为0.6%(11/1785),非携带者为0.8%(9/1125),P=0.56。
  • 安全性终点:全因死亡率在携带者为0.3%(5例),非携带者为0.1%(1例),P=0.27。

证据类型、等级与局限

  • 证据类型:前瞻性非随机临床试验(PLATELET试验),ClinicalTrials.gov Identifier: NCT04072705。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论认为,在该前瞻性非随机临床试验中,CYP2C19 LOF等位基因携带者发生心血管事件的可能性更高。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Cytochrome P450 2C19 (CYP2C19) genotypes influence the antiplatelet effectiveness of clopidogrel by affecting its conversion to its active metabolite. However, evidence from prospective trials regarding the effects of CYP2C19 genotypes on the role of clopidogrel preventing cardiovascular events among patients with acute ischemic stroke remains limited.

OBJECTIVE: To investigate the association of the CYP2C19 genotypes with the clinical prognosis of patients with acute ischemic stroke treated with clopidogrel.

DESIGN, SETTING, AND PARTICIPANTS: A prospective, nonrandomized clinical trial was conducted from September 1, 2019, to January 27, 2023, at 37 clinical sites in South Korea. Patients who received clopidogrel within 72 hours of experiencing an acute ischemic stroke were included.

INTERVENTIONS: Patients were classified using CYP2C19 genotyping into carrier and noncarrier of CYP2C19 loss-of-function (LOF) allele. Clopidogrel treatment was maintained throughout the study period.

MAIN OUTCOMES AND MEASURES: The primary outcome was the difference in the risk of cardiovascular events (including ischemic or hemorrhagic stroke, myocardial infarction, or cardiovascular death) within 6 months after an ischemic stroke between patients who were carriers or noncarriers of the CYP2C19 LOF allele. The primary safety outcomes were the differences in all-cause mortality and the occurrence of major bleeding. Intention-to-treat analysis was performed.

RESULTS: Overall, 2925 patients were enrolled in the PLATELET trial. The mean (SD) age of the participants was 65.3 (12.4) years, and 1928 (66.3%) were men. Among these patients, 15 were excluded. Of the remaining 2910 patients, 61.3% were classified as poor or intermediate metabolizers and 38.7% as extensive metabolizers. The primary outcome occurred more frequently in carriers of the LOF CYP2C19 allele than in noncarriers (2.7% [49 of 1785] vs 1.6% [18 of 1125]; log-rank P = .048). No significant differences were observed between CYP2C19 LOF allele carriers and noncarriers regarding the occurrence of major bleeding (0.6% [11 of 1785] vs 0.8% [9 of 1125]; P = .56) and all-cause mortality (0.3% [5] vs 0.1% [1]; P = .27).

CONCLUSIONS AND RELEVANCE: In this prospective nonrandomized clinical trial, carriers of the CYP2C19 LOF allele genotype exhibited a higher likelihood of experiencing cardiovascular events.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04072705.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Jung YH, Song TJ, Kim J, et al. Cytochrome P450 2C19 Genotypes and Clopidogrel in Patients With Ischemic Stroke: A Nonrandomized Clinical Trial. JAMA Netw Open. 2025. PMID: 40184070. doi:10.1001/jamanetworkopen.2025.0398

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。